Pharmacologic and Lifestyle Interventions to Modulate the Epigenome in Heart Failure
Heart Failure Clinics · 2026
DOI: 10.1016/j.hfc.2025.08.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Heart Failure Clinics, 2026. Verfasst von Ludovica Di Venanzio und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zürich and University of Zürich, Wagistras…. Hauptthemen laut MEDLINE: Heart Failure, Life Style, Epigenesis, Genetic, Epigenome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 98 Literaturangaben. Gefördert von: Schweizerische Herzstiftung, Nemzeti Kutatási, Fejlesztési és Innovaciós Alap, Novartis Foundation.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) remains a major global health concern with high morbidity and mortality, particularly in cases with preserved ejection fraction, where treatment options are limited. Epigenetic mechanisms, including DNA methylation, histone modification, and noncoding RNAs, are increasingly recognized for their role in HF development and progression. These processes integrate genetic and environmental signals, offering novel targets for therapy. Emerging pharmacologic agents, alongside repurposed drugs with epigenetic effects, show promising results. Additionally, lifestyle factors such as diet and exercise influence the epigenome, opening new avenues for personalized, nonpharmacological interventions aimed at modifying disease trajectory and improving clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zürich and University of Zürich, Wagistrasse 12, 8952, Schlieren, Switzerland. Electronic address: ludovica.dive…
- Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zürich and University of Zürich, Wagistrasse 12, 8952, Schlieren, Switzerland.
- Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zürich and University of Zürich, Wagistrasse 12, 8952, Schlieren, Switzerland; Center for Pharmacology and Drug…
- Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zürich and University of Zürich, Wagistrasse 12, 8952, Schlieren, Switzerland; Department of Cardiology, Univers…
- Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zürich and University of Zürich, Wagistrasse 12, 8952, Schlieren, Switzerland; Department of Cardiac Surgery, Un…
Förderung
- Schweizerische Herzstiftung
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
- Novartis Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- EMDO Stiftung
- Universität Zürich
- Kurt und Senta Herrmann Stiftung
- Olga Mayenfisch Stiftung
Zitieren
APA
Di Venanzio, L., Atzemian, N., Weber, B. Y., Gorica, E., Kleeberger, J. A., Mohammed, S. A., Costantino, S., Dzemali, O., Ruschitzka, F., & Paneni, F. (2026). Pharmacologic and Lifestyle Interventions to Modulate the Epigenome in Heart Failure. Heart Failure Clinics. https://doi.org/10.1016/j.hfc.2025.08.001
Vancouver
Di Venanzio L, Atzemian N, Weber BY, Gorica E, Kleeberger JA, Mohammed SA, et al. Pharmacologic and Lifestyle Interventions to Modulate the Epigenome in Heart Failure. Heart Failure Clinics. 2026. doi:10.1016/j.hfc.2025.08.001
BibTeX
@article{DiVenanzio2026,
author = {Di Venanzio, Ludovica and Atzemian, Natalia and Weber, Bennet Y and Gorica, Era and Kleeberger, Jan Alphard and Mohammed, Shafeeq A and Costantino, Sarah and Dzemali, Omer and Ruschitzka, Frank and Paneni, Francesco},
title = {Pharmacologic and Lifestyle Interventions to Modulate the Epigenome in Heart Failure},
journal = {Heart Failure Clinics},
year = {2026},
doi = {10.1016/j.hfc.2025.08.001}
}
EUVIMED